An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Ongentys

Chemical Nameopicapone
Dosage FormCapsules (oral; 25 mg, 50 mg)
Drug ClassInhibitors
SystemNervous
CompanyNeurocrine Biosciences, Inc.
Approval Year2020

Indication

  • Indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes.
Last updated on 12/8/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Ongentys (opicapone) Prescribing Information.2020Neurocrine Biosciences, Inc., San Diego, CA
Document TitleYearSource
Parkinson’s disease with end-of-dose motor fluctuations: opicapone.2017NICE